<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565275</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00303</org_study_id>
    <nct_id>NCT04565275</nct_id>
  </id_info>
  <brief_title>A Study of ICP-192 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients&#xD;
      with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase&#xD;
      I), dose escalation and Part II (Phase II), dose expansion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I (Phase I) of the study enrolls patients with advanced solid tumors (9-15 patients);&#xD;
      Part II (Phase II) of the study enrolls patients with urothelial carcinoma or&#xD;
      cholangiocarcinoma with FGFR genetic alterations (30 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation &amp; Phase II: Dose Expansion To evaluate the safety and tolerability of different doses of ICP-192 in patients with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation To determine Maximum Tolerated Dose（MTD) for ICP-192</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OBD</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation To determine Optimal Biological Dose (OBD) for ICP-192</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation To determine Recommended Phase 2 Dose (RP2D) for ICP-192</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation Peak concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase I: Dose Escalation AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion Assessment of the correlations between drug exposure (e.g., AUC, Cmax) and patient response to ICP-192.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD biomarker</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Phase II: Dose Expansion Assessment of the correlations between PD biomarker and patient response to ICP-192.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>ICP-192</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase ICP-192&#xD;
Dose Expansion Phase ICP-192</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug ICP-192</intervention_name>
    <description>Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the &quot;3+3&quot; dose escalation scheme&#xD;
Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase.</description>
    <arm_group_label>ICP-192</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Participate voluntarily, sign informed consent, and follow the study treatment plan&#xD;
             and scheduled visits;&#xD;
&#xD;
          2. Phase I: Patients with histologically or cytologically confirmed unresectable or&#xD;
             metastatic advanced malignant solid tumors who have progressed under standard&#xD;
             treatment or recurred after or were intolerant to all standard treatment regimens, or&#xD;
             have no standard treatment available;&#xD;
&#xD;
          3. Phase II: patients with histologically or cytologically confirmed unresectable or&#xD;
             metastatic urothelial carcinoma or cholangiocarcinoma, who have progressed or recurred&#xD;
             after or were intolerant to first-line chemotherapy, or have progressed/relapsed&#xD;
             within 12 months after neoadjuvant /adjuvant chemotherapy;&#xD;
&#xD;
          4. Phase II: Existing test reports have confirmed the FGFR gene alteration or the central&#xD;
             laboratory has detected the FGFR gene alteration.&#xD;
&#xD;
          5. Age ≥18 years old;&#xD;
&#xD;
          6. At least one measurable lesion according to the Response Evaluation Criteria of Solid&#xD;
             Tumor, version 1.1 (RECIST 1.1);&#xD;
&#xD;
          7. ECOG performance status of 0-1;&#xD;
&#xD;
          8. Life expectancy for more than 3 months; Must have adequate organ function Major&#xD;
             Exclusion Criteria&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Have previously been treated with selective pan-FGFR molecular inhibitors or antibody&#xD;
             drugs, except for the FGFR4 selective inhibitors;&#xD;
&#xD;
          2. Within 2 weeks before the first dose of study drug, the subject's phosphate level&#xD;
             continuing to exceed the ULN despite medical treatment;&#xD;
&#xD;
          3. Patients with clinically significant gastrointestinal dysfunction&#xD;
&#xD;
          4. Has known central nervous system metastases;&#xD;
&#xD;
          5. Has a history of or currently uncontrolled cardiovascular diseases&#xD;
&#xD;
          6. History of organ transplantation or a history of allogeneic hematopoietic stem cell&#xD;
             transplantation;&#xD;
&#xD;
          7. Current evidence of corneal or retinal abnormalities that may increase eye toxicity;&#xD;
&#xD;
          8. Active hepatitis B virus active hepatitis C, or HIV infection;&#xD;
&#xD;
          9. Has not recovered from reversible toxicity of prior anti-tumor therapy&#xD;
&#xD;
         10. Pregnant or lactating women, as well as women with childbearing potential who are&#xD;
             unwilling or unable to perform contraception from the screening to 6 months after the&#xD;
             last study drug administration; and fertile men who are unwilling or unable to perform&#xD;
             contraception from screening to 3months after the last study drug administration&#xD;
&#xD;
         11. Other conditions considered by the investigator to be inappropriate for participation&#xD;
             in this study.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivia Yang</last_name>
    <phone>+1 (609) 524-0684</phone>
    <email>olivia.yang@INNOCAREPHARMA.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhir Manda, MD</last_name>
      <phone>520-886-0206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manojkumar Bupathi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Nash, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diaa Osman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

